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SUMMARY
Expression of the PTEN tumor suppressor is frequently lost in breast cancer in the absence of mutation or
promoter methylation through as yet undetermined mechanisms. In this study, we demonstrate that the
Rak tyrosine kinase physically interacts with PTEN and phosphorylates PTEN on Tyr336. Knockdown of
Rak enhanced the binding of PTEN to its E3 ligase NEDD4-1 and promoted PTEN polyubiquitination, leading
to PTEN protein degradation. Notably, ectopic expression of Rak effectively suppressed breast cancer cell
proliferation, invasion, and colony formation in vitro and tumor growth in vivo. Furthermore, Rak knockdown
was sufficient to transform normal mammary epithelial cells. Therefore, Rak acts as a bona fide tumor
suppressor gene through the mechanism of regulating PTEN protein stability and function.INTRODUCTION
The PTEN (phosphatase and tensin homolog deleted from
chromosome 10) tumor suppressor gene, located at chromo-
some 10q23, is frequently mutated in a number of tumor line-
ages, including glioblastoma, melanoma, and carcinomas of
the prostate, breast, and endometrium (Li et al., 1997; Li and
Sun, 1997; Steck et al., 1997). PTEN antagonizes the actions
of phosphatidylinositol 3-kinase by dephosphorylating the
second messenger phosphatidylinositol 3,4,5-trisphosphate
(Cantley and Neel, 1999; Di Cristofano and Pandolfi, 2000;
Maehama et al., 2001; Wishart and Dixon, 2002), regulating
activation of the kinase Akt as well as the downstream cellular
survival and growth responses (Bellacosa et al., 1991; Chang
et al., 1997; Jimenez et al., 1998; Staal, 1987). PTEN has phos-
phatase, C2, and PDZ binding domains as well as potential
sites of regulation by phosphorylation, including tyrosine phos-
phorylation, which may contribute to its ability to modulate cell
growth and viability.Emerging evidence shows that complete or partial loss of
PTEN protein expression, in addition to gene deletion or muta-
tion, can impact tumor suppression (Salmena et al., 2008).
Indeed, PTEN protein levels are reduced in at least 50%of breast
cancers, though gene mutations are rare (Hennessy et al., 2005;
Brugge et al., 2007; Stemke-Hale et al., 2008). The epigenetic
regulation of PTEN expression has been attributed to transcrip-
tional regulation, microRNA, and/or alteration of PTEN protein
stability (Salmena et al., 2008). The disruption of PTEN protein
stability represents a particularly attractive yet elusive mecha-
nism contributing to its loss in human cancer. Numerous reports
have suggested that PTEN stability is regulated by interaction
with other proteins and that it is subject to posttranslationalmodi-
fication, particularly phosphorylation (Salmena et al., 2008). To
better understand the regulation of PTEN phosphorylation,
stability, and function, we used a proteomics-based approach
to systematically identify PTEN-binding proteins.
Rak is a 54 kDa tyrosine kinase that belongs to the Src family of
kinases (Annere´n et al., 2003; Cance et al., 1994; Serfas andSIGNIFICANCE
PTEN protein is frequently absent in cancer, particularly breast cancer, despite a lack of gene mutation. The mechanism
causing PTEN protein loss has not been defined. Here we demonstrate that the Rak tyrosine kinase phosphorylates
PTEN, protecting it from ubiquitin-mediated degradation. Surprisingly, Rak exhibits strong tumor-suppressive activity
in vitro and in vivo, at least in part through regulating PTEN protein stability. Thus, Rakmay function as a tumor suppressor
gene, and further understanding of its functionmay contribute to effective therapeutic approaches for both Rak- and PTEN-
defective cancers.
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Rak Phosphorylates and Stabilizes PTEN ProteinTyner, 2003). Like all members of the Src kinase family, the Rak
kinase possesses an SH domain as well as conserved autoregu-
latory tyrosine residues in its catalytic domain (Annere´n et al.,
2003; Cance et al., 1994; Serfas and Tyner, 2003). However,
Rak differs significantly from the other Src family members in
many structural features, including the presence of a putative
bipartite nuclear localization signal and the lack of a consensus
myristoylation motif (Annere´n et al., 2003; Serfas and Tyner,
2003). In fact, Rak has been shown to be a nuclear protein with
growth-inhibitory effects when ectopically expressed in breast
cancer cells (Meyer et al., 2003). Notably, theRak gene is located
on chromosome 6q21-23, a region that undergoes loss of
heterozygosity in 30% of breast cancer cases (Sheng et al.,
1996). However, the mechanisms by which Rak and its
substrates function in cancer have remained unexplored. In
this study, we demonstrate the functional interaction between
Rak and PTEN and provide mechanistic evidence that Rak func-
tions as a bona fide breast tumor suppressor gene.
RESULTS
Rak Is a PTEN-Interacting Protein
To systematically identify proteins involved in regulation of PTEN
phosphorylation and/or protein turnover, we carried out immu-
noaffinity purification followed by mass spectrometry. We
demonstrated that the Rak tyrosine kinase represents one of
the major PTEN-associated proteins (Figure 1A). To validate
the mass spectrometry result, we performed immunoprecipita-
tion/western blot analysis and found that PTEN coprecipitated
with Rak (Figure 1B, left). Reciprocally, Rak could also be pulled
down when an antibody against PTEN was used for immunopre-
cipitation (Figure 1B, right). This result strongly suggests that
endogenous PTEN and Rak physically interact.
Tomap thebindingdomainonRak,weexpressedFLAG-tagged
wild-type Rak and Rak mutants lacking an SH2 domain (Rak-
DSH2) or an SH3 domain (Rak-DSH3) in U2OS cells. We found
that PTEN coprecipitated with wild-type Rak and Rak-DSH2, but
PTEN binding to Rak-DSH3 was much reduced (Figure 1C). We
also created three PTEN mutants, PTEN D1–185, PTEN D185–
352, and PTEN D353–403. As shown in Figure 1D, Rak coprecipi-
tated with wild-type PTEN and PTEN D353–403, and weakly with
PTEN D1–185. However, Rak did not bind to PTEN D185–352.
These results provide evidence that the binding of Rak and
PTEN is mediated through the interaction between the SH3
domain of Rak and the C2 domain (and perhaps the phosphatase
domain as well) of PTEN.
Previous studies have implicated both Rak and PTEN in breast
cancer. We therefore further evaluated the correlation between
Rak and PTEN protein expression in breast cancer tissues by
linear correlation analysis. Among the 42 cases analyzed, Rak
expressionshowedastrongpositivecorrelationwith thatofPTEN
(32 cases, 76.19%) (R2 = 0.8039, p < 0.01) (Figure 1E). High
expression of Rak but low expression of PTEN was detected
in 7 cases (16.67%), possibly due to PTEN deletion or mutation
in breast cancer. There were only 3 cases that showed low
expression of Rakbut high expression of PTEN (Figure 1E). These
data suggest a potential link between expression of PTEN and
Rak in breast cancer cells.Rak Regulates PTEN Protein Stability
Next, we sought to determine whether there is a causal relation-
ship between Rak status and PTEN protein levels. To this end,
we established two Rak-overexpressing MCF7 breast cancer
cell lines (Rak 44 and Rak 45; Figure 1F, left) and three stable
Rak-knockdown nontumorigenic MCF10A cell lines (Rak KD1,
Rak KD2, and Rak KD3; Figure 1F, right). Interestingly, we found
that Rak positively regulated PTEN protein expression without
affecting PTEN mRNA levels (Figure 1G). PTEN protein expres-
sion was significantly increased in the Rak-overexpressing
MCF7 cells and was abolished in the Rak-knockdown MCF10A
cells.
We further tested whether PTEN activity and levels of its
downstream targets were also affected by enforced changes
in Rak levels. As shown in the top left panel of Figure 1H, the lipid
phosphatase activity of PTEN was increased by 60% when Rak
was ectopically expressed in MCF7 cells, suggesting that Rak
enhances the capacity of PTEN to dephosphorylate phosphati-
dylinositol. Consistently, Rak overexpression increased the
inhibitory effects of PTEN on downstream targets in the PI3K
pathway. We found that overexpression of Rak reduced Akt
phosphorylation (Figure 1H, top right) and repressed b-catenin
nuclear localization and activity as indicated by reporter
constructs containing three repeats of wild-type (TOP) or mutant
(FOP) Tcf4 (T cell factor)-binding sites (Figure 1H, bottom). PTEN
has previously been shown to inhibit nuclear b-catenin
accumulation as well as b-catenin transactivation activity
(Persad et al., 2001). Thus, these data indicate that enforced
Rak expression increases PTEN activity, reducing Akt phos-
phorylation and blocking its downstream signaling. It is worth-
while to note that the MCF7 cells used in our study express
the wild-type Akt and therefore are very suitable for the purpose
of this study.
SinceRakbinds toPTENandpositively regulatesPTENprotein
expression, we suspected that Rak might regulate PTEN protein
stability. To test this possibility, we compared PTEN protein turn-
over between control and Rak-knockdown cells in the presence
of cycloheximide (CHX), which blocks protein synthesis. As
shown in Figure 1I, Rak knockdown led to a reduction in the
half-life of PTEN protein from more than 24 hr to less than 6 hr,
indicating an essential role of Rak in the stabilization of PTEN
protein. Overexpression of Rak also increased the half-life of
PTEN in other cell lines, such as the U2OS cells used above
(see Figure S1A available online).
PTEN Ubiquitination Is Accelerated in the Absence
of Rak
TodeterminewhetherRak regulatesPTENproteinstability through
theproteasomalpathway,we treatedcontrol andRak-knockdown
cells with a 10 mM concentration of the proteasome inhibitor
MG132. MG132 treatment substantially increased PTEN protein
levels in Rak-knockdown cells but only slightly increased PTEN
expression levels in control cells (Figure 2A), indicating that Rak
protects PTEN from proteasome-dependent degradation.
It has recently been reported that PTEN protein levels are
regulated in part by proteasomal degradation through the ubiq-
uitin ligase NEDD4-1 (Wang et al., 2007). To investigate whether
Rak regulates PTEN ubiquitination, we performed an in vivo
ubiquitination assay. First, MCF7 cells were cotransfected withCancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc. 305
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Rak Phosphorylates and Stabilizes PTEN ProteinFigure 1. Rak Binds to PTEN and Regulates PTEN Protein Stability
(A) Silver staining of the PTEN complex separated by SDS-PAGE.Whole-cell extracts were prepared fromU2OS cells transiently transfectedwith empty vector or
FLAG-PTEN.306 Cancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc.
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Rak Phosphorylates and Stabilizes PTEN Proteinplasmids encoding FLAG-tagged Rak, His-tagged PTEN, HA-
tagged ubiquitin, and/or combinations of control vectors. The
expressed His-tagged PTEN was then pulled down from cell
lysates with Ni2+-nitrilotriacetic acid resin. Subsequently,
western blotting against the HA tag was performed to detect
ubiquitinated PTEN. As predicted, in the absence of ectopic
expression of Rak, PTEN protein was heavily ubiquitinated,
with a characteristic ladder indicative of polyubiquitination (Fig-
ure 2B, lane 6); in the presence of Rak, PTEN ubiquitination
was decreased (Figure 2B, lane 5). Consistently, we also found
that PTEN polyubiquitination was increased in the absence of
Rak in MCF10A cells and that the treatment of cells with the pro-
teasome inhibitor MG132 caused a robust increase of polyubi-
quitinated PTEN protein (Figure 2C).
In support of a role for Rak in PTEN polyubiquitination, we
demonstrated that Rak altered the binding of PTEN with its E3
ligase NEDD4-1. As shown in Figure 2D, Rak knockdown in
MCF10A cells resulted in a substantial increase in the associa-
tion between endogenous PTEN and NEDD4-1 as indicated by
coimmunoprecipitation. Furthermore, PTEN polyubiquitination
was significantly decreased in the absence of NEDD4-1
(Figure 2E, lane 2 versus lane 6). Together, our findings strongly
indicate that >Rak stabilizes PTEN protein through blocking
ubiquitin-mediated proteasomal degradation, likely through
reducing PTEN binding to NEDD4-1.
Rak Phosphorylates PTEN on Tyr336
In light of our finding that PTEN is a binding partner of Rak, we
investigated whether PTEN is a Rak substrate. In an in vitro
kinase assay, Rak could indeed induce PTEN phosphorylation
(Figure 3A). Consistently, using a phosphotyrosine antibody,
we confirmed the phosphorylation of endogenous PTEN in
MCF7 cells stably overexpressing Rak (Figure 3B). Interestingly,
whenwe tested several PTENmutants in which tyrosine residues
that could play a role in the interaction of PTEN with the
membrane were mutated, we found that mutation of Tyr336
abolished the phosphorylation of PTEN by Rak. Furthermore,
a kinase-dead Rakmutant (K262R) was unable to phosphorylate
PTEN (Figure 3C), suggesting that Rak may directly phosphory-
late PTEN in intact cells.Phosphorylation of Tyr336 by Rak Is Required
for Maintenance of PTEN Protein Stability
Our studies indicated that Tyr336 of PTEN is required for PTEN
phosphorylation by Rak. To explore the functional significance
of this phosphorylation, we ectopically expressed either wild-
type or Y336F mutant PTEN in cells and measured protein
half-lives. As shown in Figure 3D, Y336F mutant PTEN was
present at a moderately lower level than wild-type PTEN. Addi-
tionally, when cells were treated with CHX, Y336F mutant
PTEN had a half-life of less than 4 hr, compared to greater
than 24 hr for wild-type PTEN (Figure 3D). Furthermore, Y336F
mutant PTEN levels were markedly increased by treatment
with the proteasome inhibitor MG132 (Figure 3E). Consistent
with the lack of phosphorylation by Rak, the association between
Y336F mutant PTEN and its E3 ligase NEDD4-1 was significantly
increased (Figure 3F).
To determine whether phosphorylation of Y336 by Rak is func-
tionally important, we compared the phosphatase activity and
the growth-inhibitory effect of ectopically expressed wild-type
and Y336F mutant PTEN on PTEN-deleted MDA-MB-468 breast
cancer cells (mutant PTEN) with or without knockdown of the
endogenous Rak gene. As shown in the top panel of
Figure 3G, we successfully generated two stable Rak-knock-
down MDA-MB-468 clones, Rak KD1 and Rak KD3. We then
stably expressed either wild-type or Y336F mutant PTEN in the
individual Rak KD1 and Rak KD3 MDA-MB-468 clones. As
shown in the bottom panel of Figure 3G, the protein level of the
Y336F mutant was lower than that of wild-type PTEN in control
MDA-MB-468 cells. The lower level of the Y336F mutant was
due to its reduced protein stability, which could be rescued by
adding the proteasome inhibitor MG132 (Figure S2). Moreover,
knockdown of Rak resulted in decreased levels of wild-type
PTEN protein without detectable effects on the level of Y336F
mutant PTEN, supporting a critical role of Rak in stabilizing
PTEN through phosphorylation of Tyr336. Also, as expected,
cells expressing Y336F mutant PTEN exhibited significantly
lower phosphatase activity compared to cells expressing wild-
type PTEN (Figure 3H). Together, these data indicate that phos-
phorylation of PTEN on Tyr336 by Rak is required for optimal
protein stability.(B) Rak associates with PTEN in cells. Cell lysates from U2OS cells were immunoprecipitated with anti-Rak, anti-PTEN, or preimmune IgG and immunoblotted
with anti-PTEN or anti-Rak antibody.
(C) Mapping the PTEN binding domain of Rak. PTEN interacts with the Rak-SH3 domain.
(D) Mapping the Rak binding domain of PTEN.
(E) Correlation of PTEN and Rak protein expression in breast cancer tissue samples (R2 = 0.8093, p < 0.01). Protein intensity was normalized to b-actin. The top
panel is a representative western blot showing the expression of Rak and PTEN in part of the samples analyzed.
(F) Left: expression of RakmRNA and protein in control MCF7 cells and Rak-overexpressingMCF7 cells (Rak 44 and Rak 45). Right: expression of RakmRNA and
protein in control MCF10A cells and Rak-knockdown MCF10A cells (Rak KD1, Rak KD2, and Rak KD3). Con, nontarget siRNA included as a negative control.
(G) PTEN is regulated by Rak at a posttranslational level. Left: expression of PTENmRNA and protein in control MCF7 cells and Rak-overexpressing MCF7 cells.
Right: expression of PTEN mRNA and protein in control MCF10A cells and Rak-knockdown MCF10A cells.
(H) Rak enhances PTEN activity and inhibits downstream targets of PTEN. Top left: effect of Rak on PTEN lipid phosphatase activity in Rak-overexpressingMCF7
cells. The capacity of immunoprecipitated PTEN to dephosphorylate water-soluble diC8-phosphatidylinositol 3,4,5-trisphosphate in control or Rak-overexpress-
ing MCF7 cells was evaluated. Top right: Akt phosphorylation at Ser473 and Thr308 is reduced in Rak-overexpressing MCF7 cells compared to MCF7 control
cells. Akt protein is shown as a loading control. Bottom left: Rak inhibits nuclear translocation of b-catenin. Lysates from MCF7 control or Rak-overexpressing
MCF7 cells were fractionated into nuclear and cytoplasmic fractions, and 40 mg of protein for each fraction was analyzed by western blotting. Bottom right:
relative b-catenin/Tcf4 activity in MCF7 control or Rak-overexpressing MCF7 cells measured as the ratio of TOP to FOP luciferase activity. Data represent
the mean ± SD of at least three independent experiments.
(I) PTEN turnover is reduced in the absence of Rak. Control or Rak-knockdownMCF10A cells were incubated with 10 mg/ml cycloheximide (CHX) for the indicated
periods of time to inhibit protein synthesis. Lysates were harvested from the cells and analyzed by western blotting.Cancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc. 307
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Rak Phosphorylates and Stabilizes PTEN ProteinFigure 2. Ubiquitination of PTEN Is Accelerated in the Absence of Rak
(A) The proteasome inhibitor MG132 effectively rescues the expression level of PTEN in Rak-knockdown cells. Control (Con) or Rak-knockdown MCF10A cells
were treated with 10 mMMG132 for 6 hr and probed for PTEN expression by western blotting. Data represent the mean ± SD of at least three independent exper-
iments.
(B) Rak inhibits ubiquitination of PTEN. MCF7 cells were cotransfected with plasmids encoding FLAG-Rak, HA-tagged ubiquitin, and His-tagged PTEN. Twenty-
four hours after transfection, cells were harvested and lysed. His-tagged PTEN was pulled down with Ni2+-nitrilotriacetic acid resin, washed, and subjected to
immunoblotting with anti-HA to detect ubiquitinated PTEN.
(C) Endogenous PTEN ubiquitination. Control or Rak-knockdown MCF10A cells were treated with or without 10 mM MG132 for 6 hr and then harvested and
analyzed. PTEN levels were normalized prior to immunoprecipitation by loading proportionally different amounts of cell extracts.
(D) The interaction between the endogenous E3 ligase NEDD4-1 and substrate PTEN is markedly increased in the absence of Rak. Proteins immunoprecipitated
from control or Rak-knockdown MCF10A cell lysates with anti-PTEN or anti-NEDD4-1 antibody were resolved by SDS-PAGE and immunoblotted with anti-
NEDD4-1 or anti-PTEN antibody as indicated.
(E) PTEN ubiquitination was significantly decreased by NEDD4-1 knockdown.In control MDA-MB-468 cells, ectopic expression of wild-type
PTEN significantly inhibited cell proliferation. In contrast, the
Y336F mutant exerted a less growth-inhibitory effect consistent308 Cancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc.with its low level of expression. Strikingly, the growth-inhibitory
effect of wild-type PTEN was reversed when Rak was knocked
down in the cells (Figure 3I). Together, these results suggest
Cancer Cell
Rak Phosphorylates and Stabilizes PTEN Proteinthat phosphorylation of Y336 by Rak prevents PTEN degrada-
tion; loss of Rakmarkedly decreased the ability of PTEN to inhibit
tumor cell growth.
Rak Suppresses Tumorigenicity of Human Breast
Cancer Cells
Since we found that Rak regulates the stability of PTEN protein
and that mutation of the Rak phosphorylation site on PTEN
decreases the growth-inhibitory effect of the PTEN tumor
suppressor gene, we posited that Rakmight function as a tumor
suppressor gene. To test this possibility, we first examined the
phenotypic characteristics of cells ectopically expressing Rak.
Interestingly, we observed marked morphologic differences
between Rak-overexpressing MCF7 stable cells and control
cells.Whereas the control cells were rounded, Rak-overexpress-
ing cells (Rak 44 and Rak 45) developed a more stellate shape
closer to the morphology of normal breast cells (Figure 4A).
Moreover, overexpression of Rak repressed proliferation
(Figure 4B) and growth in soft agar of MCF7 cells (Figure 4C)
as well as other cell lines, such as the U2OS cells used above
(Figures S1B and S1C). Rak overexpression also suppressed
tumor cell invasion in a Matrigel invasion assay that mimics the
extracellular matrix in vivo (Figure 4D).
Given that Rak effectively suppressed phenotypes associated
with in vitro transformation, we investigated the effect of Rak
expression in a xenograft mouse model. Mice were injected in
the mammary glands with Rak-overexpressing MCF7 cells or
vector control MCF7 cells and monitored weekly for tumor
formation. By week 8, all ten of the mice injected with Rak-over-
expressing clones remained tumor free, whereas all five of the
control mice had developed tumors (Table 1; Figure 4E).
Rak Knockdown Transforms Normal Mammary
Epithelial Cells
As shown above, Rak overexpression suppressed invasion and
proliferation of breast cancer cells both in vitro and in vivo. To
further assess whether Rak is a bona fide breast tumor
suppressor gene, we sought to determine whether loss of Rak
expression would transform normal mammary epithelial cells.
Transformation activity in vitro and tumorigenicity in vivo were
evaluated using the three Rak-knockdown MCF10A cell lines
described above. Rak knockdown promoted cell proliferation
(Figure 5A), anchorage-independent growth (Figure 5B), and
in vitro invasive potential (Figure 5C). Notably, when Rak was
depleted in MDA-MB-468 (PTEN mutant) cells, its effects on
proliferation and anchorage-independent growth were less
evident (Figure 3I; Figure S3), suggesting that PTEN is one of the
major targets mediating Rak suppression of cell transformation.
We also investigated whether Rak knockdown in MCF10A
cells would allow tumor formation in xenografts. We injected
control cells or individual Rak-knockdown clones into mammary
glands of nude mice and monitored tumor growth. Notably, all of
the mice injected with Rak-knockdown cells, but none of the
mice injected with control vector-expressing cells, developed
tumors within 3 weeks after injection (Table 2; Figure 5D). Path-
ologic analysis of the tumors revealedmicropapillary hyperplasia
in Rak-knockdown clones (Figure 5E). These results demon-
strate that loss of Rak is sufficient to induce tumorigenicity inimmortalized normal mammary epithelial cells, supporting
a role for Rak as a bona fide tumor suppressor in breast cancer.
DISCUSSION
Previous studies have demonstrated that tumor-associated
PTEN mutations frequently lead to loss of PTEN protein, with
at least 20%of the cases demonstrating highmRNA levels indic-
ative of rapid degradation of mutant PTEN protein in cells (Geor-
gescu et al., 1999). In fact, PTEN tyrosine mutants, with an asso-
ciated loss of PTEN protein and tumor suppressor activity, have
been detected in many types of cancer. However, little is known
about the mechanisms that regulate PTEN protein stability and
whether the molecules regulating PTEN stability also function
as tumor suppressor genes in human cancer. In this study, we
found that expression of Rak, a PTEN-interacting protein,
strongly correlates with PTEN protein levels in breast cancer
tissues, and we demonstrated that Rak positively regulates
PTEN protein stability through phosphorylation of PTEN on
Tyr336, which in turn prevents PTEN from ubiquitination and
degradation.
Recent studies have shown that PTEN protein stability is regu-
lated by ubiquitin-mediated proteasomal degradation through
the E3 ligase NEDD4-1. As with PTEN stability, the mechanisms
regulating NEDD4-1 and PTEN association have not been fully
elucidated. Since Rak enhances PTEN stability, we suspected
that phosphorylation of NEDD4-1 or PTEN by Rak might disrupt
the interaction between these twomolecules and in turn stabilize
PTEN protein. In our studies, we found that Rak efficiently phos-
phorylates PTEN on Tyr336 but has no detectable kinase activity
toward NEDD4-1 (data not shown). Notably, Rak depletion
increased the interaction between NEDD4-1 and PTEN, sug-
gesting that phosphorylation of PTEN by Rak may inhibit PTEN
binding to NEDD4-1 and subsequent PTEN degradation. Indeed,
negative regulation of the binding between E3 ligase and
substrate as a consequence of tyrosine phosphorylation has
previously been reported. For example, Fyn has been shown to
phosphorylate the E3 ubiquitin ligase Itch and to reduce its
binding to and degradation of its substrate JunB (Yang et al.,
2006). Notably, Fyn and Rak belong to the same kinase family,
and Itch is a HECT-type E3 ligase, like NEDD4-1. Thus, the regu-
latory mechanisms are similar, except that Rak phosphorylates
the substrate whereas Fyn phosphorylates the E3 ligase. It is
tempting to speculate that tyrosine phosphorylation may be
a commonmechanism for regulation of protein stability, in which
tyrosine kinases protect substrates fromHECT-mediated degra-
dation. This mechanism is in contrast to the one by which serine/
threonine kinases promote F box-containing E3 ligase-mediated
ubiquitination and protein degradation.
In addition to elucidating a mechanism that regulates PTEN
protein stability, as illustrated in Figure 6, our studies also iden-
tified Rak as having the potential to act as a tumor suppressor
gene in breast cancer. Rak is located a region that undergoes
loss of heterozygosity in 30% of breast cancer cases. However,
the role of Rak in breast cancer development is far from clear.
Although we identified PTEN as an important substrate for Rak
and one that may play crucial role in Rak’s tumor suppressor
function, we cannot rule out the possibility that Rak may also
suppress tumor growth through one or more PTEN-independentCancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc. 309
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Rak Phosphorylates and Stabilizes PTEN ProteinFigure 3. Rak Phosphorylates PTEN on Tyr336 to Prevent Its Protein Degradation
(A) Rak induces PTEN phosphorylation. Recombinant Rak was incubated with His-PTEN in the presence of [g-32P]ATP. PTEN phosphorylation was then exam-
ined by autoradiography.
(B) Endogenous PTEN was immunoprecipitated from Rak-overexpressing MCF7 cells or control cells and blotted with antibodies against phosphotyrosine or
PTEN. PTEN levels were normalized prior to immunoprecipitation by loading proportionally different amounts of cell extracts.
(C) PTEN Tyr336 is phosphorylated by Rak. Recombinant wild-type Rak or its kinase-inactive mutant (K262R) was incubated with FLAG-PTEN or the Y/F PTEN
mutants (Y68F, Y240F, Y315F, and Y336F) in the presence of [g-32P]ATP. PTEN phosphorylation was determined by autoradiography.
(D) Y336F mutant PTEN protein is less stable than wild-type PTEN. Ectopic expression of wild-type (WT) or Y336F mutant PTEN in U2OS cells was measured for
12 hr after CHX treatment.
(E) The proteasome inhibitor MG132 stabilizes Y336F mutant PTEN protein. U2OS cells were treated with 10 mM MG132 for 6 hr.
(F) The E3 ligase NEDD4-1 has higher binding affinity to the Y336F mutant than to the wild-type PTEN.
(G) Top: Rak expression levels in nontarget shRNA control (Con) or Rak-knockdown MDA-MB-468 cells were analyzed by western blotting. Bottom: protein
expression levels of wild-type or Y336F mutant PTEN were analyzed in control (NT) and Rak-knockdown MDA-MB-468 cell lines.310 Cancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc.
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Rak Phosphorylates and Stabilizes PTEN Proteinpathways. PTEN has been reported to play fundamental roles in
the maintenance of chromosomal stability as well as stem cell
biology. Thus, we speculate that Rak may also participate in
these two important biological functions. In fact, our preliminary
studies implicate Rak in preventing spontaneous DNA damage
(data not shown). Thus, we will determine how Rak regulates
genomic integrity and whether Rak is involved in ‘‘stemness’’
of cells in future studies.
EXPERIMENTAL PROCEDURES
Cell Culture and Plasmids
U2OS cells and breast cancer cell lines were purchased from the American
Type Culture Collection. U2OS cells were maintained in McCoy’s 5A medium
(Cellgro) supplemented with 10% FBS with glutamine, penicillin, and strepto-
mycin. MDA-MB-468 breast cancer cells were grown in RPMI 1640 medium
supplemented with 10% FBS. MCF7 cells were maintained in DMEM/nutrient
mixture F12 (Cellgro) supplemented with 10% FBS. MCF10A cells were main-
tained in mammary epithelial growth medium (Clonetics), a proprietary serum-
free medium containing insulin, hydrocortisone, epidermal growth factor, and
(H) Lipid phosphatase activity of wild-type or Y336F mutant PTEN was evaluated in the control or Rak knockdown MDA-MB-468 cells.
(I) Wild-type PTEN, but not Y336F mutant PTEN, effectively inhibited the proliferation of MDA-MB-468 cells in a Rak-dependent manner. Data represent the
mean ± SD of at least three independent experiments.
Figure 4. Rak Suppresses Tumorigenicity
of MCF7 Breast Cancer Cells
(A) Rak induces a striking morphologic change in
monolayer-culturedMCF7cells.Scalebar=50mm.
(B) Expression of Rak reduces the proliferation of
MCF7 cells. Control or Rak-overexpressing MCF7
cells were seeded in a 96-well plate at 1 3 104
cells per well. Cell proliferation was measured by
MTT assay for 5 days.
(C) Rak suppresses anchorage-independent
growth of MCF7 cells. Viable colonies of MCF7
clones in three wells were counted; all soft agar
assays were performed in triplicate.
(D) Rak suppresses invasion of MCF7 cells in Matri-
gel invasionassay.Cellsweresuspendedincollagen
type I Matrigel, and the number of invading cells in
five fields was counted under 2003magnification.
(E) Rak suppresses tumor growth. Cells were
injected into the mammary glands of nude mice
(5 3 106 cells per mouse), and tumor volumes
were measured every 2 days.
Data in (B)–(E) represent the mean ± SD of at least
three independent experiments per panel.
bovine pituitary extract. Cells were incubated at
37C in a humidified incubator with 5% CO2.
The pCMV5-3 3 FLAG vector encoding Rak
was provided by F.M.-B. The K262R point muta-
tion was created from 3 3 FLAG-Rak using the
GeneTailor Site-DirectedMutagenesis System (In-
vitrogen). The Rak deletion mutants Rak-DSH2
and Rak-DSH3 (Meyer et al., 2003) were provided
by R.J.C. pCMV5-3 3 FLAG and pCMV5-3 3
FLAG-PTEN, -PTENY68F, -PTENY240F, -PTENY315F,
and -PTENY336F were provided by G.B.M. The
PTEN deletion mutants were generated by PCR
(see Figure 1D). His-PTEN (883 pET15b PTEN)
was purchased from Addgene. Full-length
NEDD4-1 cDNA was amplified by polymerase chain reaction and subcloned
into pGEX-5T-3 (Amersham Pharmacia Biotech). The identity of all plasmids
was confirmed by sequencing at the M.D. Anderson Cancer Center DNA
Core Sequencing Facility.
Antibodies and Reagents
Nucleotides 448–1433 were subcloned into pGEX-4T with the sense primer
50-TTTTGGATCCATGAGCAACATcTGTCAGAGG-30 and the antisense primer
50-TTTTCTCGAGTTTCACTGCTACTGGAGTGGT-30, and the protein product
was used for immunization for rabbit polyclonal anti-Rak antibody (Proteintech
Group, Inc.). Anti-PTEN antibody was purchased from Cell Signaling Tech-
nology. Anti-FLAG M2 and anti-b-actin were purchased from Sigma. Cyclo-
heximide was obtained from Sigma and used at 10 mg/ml (MCF10A cells) or
40 mg/ml (U2OS cells); MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucine)
was obtained from EMD Biosciences and used at 10 mM.
Affinity Purification of PTEN Protein Complex
U2OS cells were transiently transfected with empty vector or FLAG-PTEN
plasmids. Forty-eight hours later, whole cellular extracts were prepared with
RIPA buffer (50 mM Tris-HCl [pH 7.4], 1%NP40, 0.25% sodium deoxycholate,
150 mMNaCl, 1 mM EDTA, 1mM phenylmethylsulfonyl fluoride, 1 mg/ml apro-
tinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM sodium orthovanadate, andCancer Cell 15, 304–314, April 7, 2009 ª2009 Elsevier Inc. 311
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overnight. Bead-bound immunocomplexes were eluted with 3 3 FLAG
peptide and subjected to SDS-PAGE. Silver staining was performed with a
SilverSNAP mass spectrometry kit (Pierce). Specific bands were excised
and digested, and the peptides were analyzed by mass spectrometry analysis
at the M.D. Anderson Cancer Center Proteomics Facility.
Preparation of Recombinant Proteins
The plasmids pGEX-5T-3-Rak and -NEDD4-1 were used to express recombi-
nant GST-Rak and NEDD4-1 in E. coli strain BL21 (DE3). The GST fusion
proteins were expressed by induction overnight at 25C with 0.1 mM
isopropyl-1-thio-b-D-galactopyranoside in strain BL21 and purified using
Table 1. Tumorigenicity of Orthotopically Implanted Control and
Rak-Overexpressing MCF7 Cells
Number of Mice with Tumors (%)
3 weeks 5 weeks 7 weeks 9 weeks
Control 4/5 (80) 5/5 (100) 5/5 (100) 5/5 (100)
Rak 44 0/5 0/5 0/5 0/5
Rak 45 0/5 0/5 0/5 0/5
53 106 cells from MCF7 control and two independent Rak-overexpress-
ing MCF7 cell lines (Rak 44 and Rak 45) were injected per mouse into
mammary glands of 6-week-old female nude mice. Each cell line was in-
jected in five different mice, and tumor sizes were analyzed.glutathione Sepharose 4B (Amersham Pharmacia Biotech) according to the
manufacturer’s instructions. The plasmid pET-15b PTEN-His was transformed
into strain BL21. The recombinant proteins were expressed and purified by
Ni2+-NTAaffinity chromatographyaccording tostandardprocedures. Theplas-
mids 3 3 FLAG-Rak, -RakK262R, -PTEN, -PTENY68F, -PTENY240F, -PTENY315F,
and -PTENY336Fwere transfected into 293Tcells, and fusion proteinswere puri-
fied using a FLAG fusion protein immunoprecipitation kit (Sigma).
Reverse Transcriptase-Polymerase Chain Reaction
cDNAwas transcribed using SuperScript III (Invitrogen) following themanufac-
turer’s instructions. Rak was amplified by polymerase chain reaction using the
primers 50-ATGAGCAACATCTGTCAGA-30 and 50-TCATCTTATGAAGTTATT
TGC-30. For amplification of PTEN, the primers 5-GGACGAACTGGTGTAATG
ATATG-30 and 5-TCTACTGTTTTTGTGAAGTACAGC-30 were used.
RNA Interference
RakknockdownwasachievedbyRNA interferenceusinga lentiviralvector-based
MISSION shRNA (Sigma). Lentiviral particles corresponding to the MISSION
shRNA Rak-U22322 target set were used, as well as the MISSION nontarget
shRNA control. Specificity and efficacy of the shRNA Rak procedure were
controlled by western blotting after transduction and puromycin selection in
MCF10A cells. shRNA against NEDD4-1 was purchased fromOpenBiosystems.
Immunoblotting and Immunoprecipitation
Cells were washed in PBS, and cellular proteins were extracted in modified
RIPA buffer (50 mM Tris-HCl [pH 7.4], 1%NP40, 0.25% sodium deoxycholate,
150 mMNaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mg/ml apro-
tinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mM sodium orthovanadate, andFigure 5. Loss of Rak Transforms MCF10A
Cells and Induces Their Tumorigenicity
(A) Rak knockdown enhances the proliferation of
MCF10A cells. Control or Rak-knockdown cells
were seeded in a 96-well plate at 1 3 104 cells
per well. Cell proliferation was measured by MTT
assay for 5 days.
(B) Rak knockdown induces anchorage-indepen-
dent growth of MCF10A cells. Viable colonies of
MCF10A clones in three wells were counted; all
soft agar assays were performed in triplicate.
(C) Rak knockdown increases invasion of MCF10A
cells in Matrigel invasion assay. Cells were sus-
pended in collagen type IMatrigel, and the number
of invading cells in five fields was counted under
2003 magnification.
(D) Rak knockdown induces tumorigenicity of
MCF10A cells in nudemice. Control or Rak-knock-
down MCF10A cells (Rak KD1 and Rak KD3) were
injected into mammary glands of nude mice (5 3
106 cells per mouse), and tumor volumes were
measured every 2 days.
(E) Pathologic analysis indicates that micropapil-
lary hyperplasias (arrows) form in nude mice
injected with Rak-knockdown MCF10A cells.
Scale bar = 100 mm.
Data in (A)–(D) represent the mean ± SD of at least
three independent experiments per panel.
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Rak Phosphorylates and Stabilizes PTEN Protein1 mM NaF) for 30 min at 4C. Lysates were cleared by centrifugation, and
proteins were separated by gel electrophoresis. Membranes were blocked
in Tris-buffered saline-0.1% Tween 20 (TBS-T)/5% (w/v) milk for 1 hr at
room temperature. Membranes were then incubated with primary antibodies
diluted in TBS-T/5% (w/v) milk for 2 hr at room temperature. Subsequently,
membranes were washed with TBS-T and incubated with horseradish perox-
idase secondary antibody (1:4000) (Jackson ImmunoResearch) diluted in
TBS-T/5% skimmilk. Membranes were washed in TBS-T, and bound antibody
was detected by enhanced chemiluminescence (ECL; GE Healthcare).
Immunoprecipitation was performed by incubating lysates from 5 3 106
cells with 1 mg of antibody at 4C overnight, followed by addition of 30 ml of
protein A/G-conjugated agarose beads (Santa Cruz Biotechnology). The
precipitates were washed four times with ice-cold PBS, resuspended in 63
Laemmli buffer, and resolved by SDS-PAGE followed by immunoblotting.
PTEN Lipid Phosphatase Assay
Cells were lysed in 50 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM EDTA, 10%
glycerol, 1% Triton X-100 with protease inhibitors. PTEN was immunoprecip-
itated by rabbit anti-PTEN antibody. The immunoprecipitates were washed
and incubated with water-soluble diC8-phosphatidylinositol 3,4,5-trisphos-
phate (Echelon Research Laboratories) in 100 mM Tris-HCl (pH 8.0), 10 mM
DTT at 37C for 40 min. The supernatant was collected after the reaction
and incubated with Biomol Green Reagent (Biomol) at room temperature for
30 min. PTEN activity was measured by colorimetric detection at OD650 of
the release of phosphate.
In Vitro Proliferation Assay
Cells were assayed for MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide; Sigma) reduction, a measure of mitochondrial viability. In brief,
cells were harvested from exponential-phase cultures growing in culture
medium, counted, and plated in 96-well flat-bottomed microtiter plates (200 ml
Table 2. Tumorigenicity of Orthotopically Implanted Control
and Rak-Deficient MCF10A Cells
Number of Mice with Tumors (%)
3 weeks 5 weeks 7 weeks 9 weeks
Control 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0)
Rak KD1 5/5 4/5a 3/5a 3/5a
Rak KD3 5/5 5/5 5/5 3/5a
5 3 106 cells from MCF10A control and two independent Rak-deficient
MCF10A cell lines (Rak KD1 and Rak KD3) were injected per mouse
into mammary glands of 6-week-old female nude mice. Each cell line
was injected in five different animals, and tumor sizes were analyzed.
a Somemice had to be sacrificed due to tumor burden starting at 5 weeks
after tumor inoculation.cell suspensions, 1 3 104 cells/ml). Seventy-two hours later, cells were incu-
batedwithMTT substrate (20mg/ml) for 4 hr, the culturemediumwas removed,
and DMSO was added. The optical density was measured spectrophotometri-
cally at 550 nm. Each experiment was repeated at least three times.
Soft Agar Assay
Cells were resuspended in DMEM containing 0.5% low-melting agarose
(Sigma, type VII) and 10% FBS and seeded onto a coating of 1% low-melting
agarose in DMEM containing 10% FBS. Colonies were scored 3 weeks after
preparation. Colonies larger than0.1mm indiameterwere scored as positive.
Invasion Assay
Invasion assays were carried out using a cell invasion assay kit (Chemicon)
according to themanufacturer’s instructions. Briefly, the assay was performed
in an invasion chamber consisting of a 24-well tissue culture plate with 12 cell
culture inserts. A cell suspension in serum-free culture medium was added
to the inserts, and each insert was placed in the lower chamber containing
10% FBS culture medium. After 72 hr incubation in a cell culture incubator,
invasiveness was evaluated by staining of cells that had migrated through
the extracellular matrix layer and clung to the polycarbonate membrane at
the bottom of the insert.
Tumor Growth in Nude Mice
Six-week-old female nude mice were used for experiments. All animal studies
were conducted in compliance with animal protocols approved by the
M.D. Anderson Cancer Center Institutional Animal Care and Use Committee.
Before injection of estrogen receptor-positive MCF7 cells (but not MCF10A),
mice were implanted subcutaneously with 0.72 mg 17-b-estradiol 60-day
release pellet (E2 pellet; Innovative Research of America). Mice were injected
in the mammary glands with 5 3 106 cells from various cell lines in 100 ml
PBS. After 1 week, tumors were measured every 2 days. Each cell line was
tested in five different animals.
For immunohistochemistry, tumor tissue samples were fixed in 10% buff-
ered formalin and processed for histopathologic evaluation by paraffin embed-
ding and hematoxylin and eosin staining.
Transfection and In Vivo Ubiquitination Assay
Cell culture transfection was performed using Lipofectamine 2000 (Invitrogen).
For in vivo PTEN ubiquitination assay, transfection was performedwhenMCF7
cells in 10 cm plates reached 90% confluence. Plasmids encoding PTEN,
Rak, and HA-tagged ubiquitin were used in transfections in individual experi-
ments. Forty-eight hours after transfection, cells were harvested, washed
with PBS, pelleted, and lysed in RIPA buffer. The cell lysates were then sub-
jected to affinity purification with Ni2+ resin (Amersham Pharmacia Biotech)
to precipitate His-tagged PTEN with the resin. These precipitated PTEN
proteins were separated by SDS-PAGE and detected by immunoblotting
with anti-HA antibody.Figure 6. Schematic Model of How Rak Phosphory-
lates PTEN and Protects PTEN from Ubiquitin-
Mediated Degradation
Rak phosphorylates PTEN on Tyr336, which reduces PTEN
binding to the E3 ligase NEDD4-1 and subsequent PTEN
degradation.
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Kinase reactions were performed by mixing purified His-PTEN with or without
purified Rak in kinase assay buffer containing 10 mCi [g-32P]ATP, 10 mM Tris-
HCl (pH 7.4), 10 mMMgCl2, 1.2 mMMnCl2, 2 mM sodium orthovanadate, and
20 mM ATP for 20 min at 30C. Reactions were terminated by adding SDS-
PAGE sample buffer and boiling at 100C for 5 min. Proteins were resolved
by SDS-PAGE and transferred onto nitrocellulose membranes for exposure
to X-ray film.
Analysis of PTEN and Rak Expression in Breast Cancer Samples
The proteins in 42 breast cancer tissue samples obtained from the institutional
breast cancer bank were extracted by RIPA buffer and analyzed for expression
of Rak andPTEN. After western blotting analysis, the intensity of Rak andPTEN
bands was quantitated, and the relationships between Rak and PTEN protein
expressionwere analyzed by linear regression. p < 0.05 was considered signif-
icant. This study was performed according to protocols approved by the M.D.
Anderson Cancer Center Institutional Review Board, and all subjects provided
written informed consent.
SUPPLEMENTAL DATA
The Supplemental Data include three figures and can be found with this article
online at http://www.cancercell.org/supplemental/S1535-6108(09)00043-9.
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